StreetAlpha.app
Home › Stocks › ALNY

Alnylam Pharmaceuticals, Inc. (ALNY)

Healthcare
$156.50
▼ −2.02%
LAST CLOSE · NOV 17

Alnylam Pharmaceuticals develops RNA interference medicines for rare and cardiovascular diseases from its base in Cambridge, Massachusetts. It last closed at $156.50 on Nov 17, down 2.02% on the day. ALNY reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 17 analysts is $284.24 (+81.6% from the last close), with a high of $380.00 and a low of $199.00. Analyst consensus is Buy, based on the latest ratings from 17 firms (11 buy, 6 hold, 0 sell). Over the past 90 days StreetAlpha recorded 12 whale options trades in ALNY, 42% of them bullish and 58% bearish. In the past 30 days there were 13 dark pool prints totaling $40.5M, the largest $9.6M.

AI Auto Pilots
Is ALNY in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$5.0B
+56.2% vs a year ago
Net income
$2.6B
+2136.9% vs a year ago
EPS (diluted)
$19.24
+2137.2% vs a year ago
Free cash flow
$806.3M
16.1% margin
Valuation
Market cap
$21.0B
133.9M shares
P/E
8.1
Price over 12 month EPS
Price to sales
4.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.8B
At Sep 30
Shareholder equity
$3.6B
Shares outstanding
133.9M
At Oct 23
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $844.3M$844.3MFY2021FY2022: $1.0B$1.0BFY2022FY2023: $1.8B$1.8BFY2023FY2024: $2.2B$2.2BFY2024FY2025: $3.7B$3.7BFY2025

From ALNY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Feb 11
2027 · Time not announced
Consensus EPS forecast
$1.72
$1.53B revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Buy
Based on 17 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
17firms
11 Buy6 Hold0 Sell
Each firm's latest rating on ALNY in the past 90 days
Average 12-month target
$284.24
▲ 81.6% upside

Based on 17 analysts who set a price target on ALNY in the past 90 days. The average target is $284.24, with a high of $380.00 and a low of $199.00, compared with the last close of $156.50.

Low $199.00Avg $284.24High $380.00
Blue marker: last close $156.50
Highest target$380.00
Average target$284.24
Lowest target$199.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 17Buy$455 → $250
Cantor FitzgeraldMaintained
Nov 17Hold$205
BarclaysTarget lowered
Nov 2Buy$450 → $380
Truist SecuritiesDowngrade
Nov 2Hold$315 → $225
Canaccord GenuityMaintained
Nov 2Buy$323
DateFirmActionRatingPrice target
Nov 17HC Wainwright & Co.Target loweredBuy$455 → $250
Nov 17Cantor FitzgeraldMaintainedHold$205
Nov 2BarclaysTarget loweredBuy$450 → $380
Nov 2Truist SecuritiesDowngradeHold$315 → $225
Nov 2Canaccord GenuityMaintainedBuy$323
Loading…

Technical Analysis

ALNY · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 15% below its 20 day and 37% below its 50 day average. It is 75% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 31), near oversold. The nearest support is the swing low (Nov 2) at $156.00, and the nearest resistance the Pivot at $157.64.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 6.4%/day
Key levels
$479.7952 week high+206.6%
$273.68200 day average+74.9%
$236.62100 day average+51.2%
$232.88Swing high (Oct 28)+48.8%
$215.0550 day average+37.4%
$179.9920 day average+15.0%
$159.49Pivot R1+1.9%
$157.64Pivot+0.7%
$156.50Last close
$156.00Swing low (Nov 2)−0.3%
$154.65Pivot S1−1.2%
$149.1852 week low−4.7%
Indicators
RSI (14)31.17Weak, oversold below 30Neutral
MACD-18.47Above its signal lineBullish
Stochastic15.1Near the bottom of its rangeOversold
ADX (14)31.8Trending down
Williams %R-86.2Oversold below −80, overbought above −20Oversold
CCI (20)-56.6Oversold below −100, overbought above 100Neutral
Rate of change−2.1%Change over 10 sessionsBearish
ATR (14)$9.99Typical daily range, 6.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ALNY

What happened before

See how ALNY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow is mixed5 bullish and 7 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow ALNY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ALNY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
12
Bullish
5
42%
Bearish
7
58%
Date span
Aug 20 – Nov 13
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
13
Notional
$40.5M
Largest print
$9.6M
Loading…

ALNY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●381 buying vs 404 selling
  • ▲Held by funds +3.9 pts
  • ▼Funds holding -65
  • ▼Superinvestors: 1 added, 2 cut
  • ▼Put/call 0.56 to 0.64
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding733798−8.1%
In funds' top 1036−50.0%
Held by funds104.7%100.8%+3.9 pts
New / increased88 / 29381 / 324−5.9%
Reduced / sold out257 / 147282 / 87+9.5%
Put/call ratio0.640.56+13.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALNY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALNY is in one of them and how their past ALNY trades turned out.

ALNY in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALNY in an article yet. Here's the latest on the wider market.

ALNY Congress Trades

All congress trades →
Trades, 12 months
8
Buys
5
63%
Sells
3
38%
People
2
Last filed Sep 22
Who traded ALNY · since 2018
Latest 5 filings of 21
$1K – $15KTraded Aug 28, 2026Filed Sep 22, 2026
$1K – $15KTraded Aug 10, 2026Filed Sep 22, 2026
$1K – $15KTraded Jul 17, 2026Filed Sep 22, 2026
$1K – $15KTraded Aug 11, 2026Filed Sep 9, 2026
$1K – $15KTraded May 18, 2026Filed Jul 1, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchBuy$1K – $15KAug 28, 2026Sep 22, 202625 d
Donald J TrumpExecutive branchBuy$1K – $15KAug 10, 2026Sep 22, 202643 d
Donald J TrumpExecutive branchBuy$1K – $15KJul 17, 2026Sep 22, 202667 d
Cory BookerD · NJSell$1K – $15KAug 11, 2026Sep 9, 202629 d
Donald J TrumpExecutive branchSell$1K – $15KMay 18, 2026Jul 1, 202644 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines based on RNA interference, a natural process cells use to switch off specific genes. Its approved treatments address hereditary transthyretin amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, high cholesterol and hemophilia, with some sold through partners. Its customers are patients with rare and cardiovascular diseases, along with the doctors and health systems that treat them.

Headquarters
Cambridge, MA
Founded
2002